American Society of Clinical Oncology (ASCO) Annual Meeting 2025

American Society of Clinical Oncology (ASCO) Annual Meeting 2025

Oncology

Overview

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago, Illinois, under the theme “Driving Knowledge to Action: Building a Better Future”. Here are some key highlights:Over 5,400 presentations covered cutting-edge research, clinical trials, and treatment innovations across a wide range of cancers.

Breast, lung, ovarian, and colorectal cancers were among the most featured tumor types. Astra Zeneca and Daiichi Sankyo presented promising results from the DESTINY-Breast09 study, suggesting a potential new standard of care for HER2-positive metastatic breast cancer.

Gilead and Merck & Co made headlines with their TROP-2–targeted therapy Trodelvy combined with Keytruda, showing strong results in triple-negative breast cancer. Amgen’s Imdelltra showed significant benefit in small cell lung cancer, a notoriously tough-to-treat disease.

In ovarian cancer, the ROSELLA trial and OVATION-2 study offered encouraging data for patients with resistant or advanced disease The target audience for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is impressively broad, reflecting the multidisciplinary nature of cancer care.

Course Details

• Price: $150.00
• Access Type: Lifetime
• Delivery Method: Google Drive Link, Offline
• Content Format: Mixed

What's Included

• Video lectures and recordings

Target Audience

• Residents
• Fellows
• Physician
• Students
• Nurses
• NP
• Specialists
• Primary Care

Key Features

• Expert-led instruction and content
• Comprehensive coverage of topic area
• Flexible learning schedule
• Lifetime access to all materials